Anand Shah
- CEO, Aster Insights;
- Operating Advisor, Clayton, Dubilier & Rice;
- Adjunct Professor of Health Policy and Medical Ethics, University of Pennsylvania;
- Deputy Commissioner for Medical and Scientific Affairs, Food and Drug Administration (2020-2021);
- Senior Medical Advisor, Centers for Medicare & Medicaid Services (2019-2020);
- Chief Medical Officer, Center for Medicare & Medicaid Innovation (2017-2019); Oncologist
Travels From
District of Columbia
Anand Shah Speaker Biography
Anand Shah, M.D. is the CEO of Aster Insights, the leading provider of scientific and clinical intelligence for oncology discovery. He is also an Operating Advisor at global private equity firm Clayton, Dubilier & Rice where he focuses on the healthcare and pharmaceutical services sectors.
Dr. Shah is a nationally recognized physician leader and health policy expert with extensive healthcare experience as an industry leader, physician, and in the senior-most levels of the U.S. government. He was previously the Deputy Commissioner for Medical and Scientific Affairs at the U.S. Food and Drug Administration (FDA). Dr. Shah led consensus policy development for fit-for-purpose programs including Advanced Manufacturing, the Coronavirus Treatment Acceleration Program, Covid vaccine development, digital health, consumer protection, and decentralized clinical trials. During the Covid pandemic, he led FDA’s policy development for preparedness and recovery efforts. Dr. Shah represented FDA with top-level policy makers of the White House and Cabinet, Governors and local governments, and regularly led briefings with Congressional leadership.
He previously served in two senior leadership roles at the Centers for Medicare & Medicaid Services (CMS). As Senior Medical Advisor, he was the primary counselor for agency-wide policy related to medical and scientific innovation. As the Chief Medical Officer of the Center for Medicare & Medicaid Innovation (CMMI), Dr. Shah led the clinical design of novel value-based payment and service delivery models including those for primary and specialty care.
Dr. Shah specializes in the early detection, surveillance, and treatment of prostate cancer, and previously developed and led a survivorship clinic for patients on cancer clinical trials at the National Institutes of Health. His scientific track record includes publications in the New England Journal of Medicine, JAMA, Health Affairs, Cancer, and Nature Reviews Drug Discovery. Dr. Shah is an Adjunct Professor of Medical Ethics and Health Policy and an Adjunct Senior Fellow at the Leonard Davis Institute of Health Economics, both at the University of Pennsylvania.
Dr. Shah was chief resident during his radiation oncology residency at Columbia University. He concurrently earned his M.D. from the University of Pennsylvania and an M.P.H. in health care management and policy from the Harvard School of Public Health. Dr. Shah graduated with honors from Duke University with a degree in economics. He also served as a Canada-U.S. Fulbright Scholar.
Leadership and Management in a Public Health Crisis
During the COVID-19 pandemic, Dr. Shah worked closely with industry, academic, and government leaders to develop strategies related to testing, therapeutics, and vaccines. He led the development of FDA’s COVID-19 Pandemic Recovery and Preparedness Plan. Dr. Shah contextualizes these experiences and discusses the importance of an integrated approach to early recognition and action, operations, crisis communications and policy, and preventing the next public health crisis. He educates leaders on the importance of using a structured approach to distilling lessons learned in order to inform future organizational strategic planning.
Reforming Medicare: Road Ahead for Primary and Specialty Care in the United States
As a leading health care expert and oncologist caring for the elderly, Dr. Shah shares his experiences navigating and shaping primary and specialty care in America. He focuses his presentation on potential solutions to the problems Medicare beneficiaries encounter related to a fragmented health care system. Dr. Shah discusses in depth the critical political, economic, and data challenges in implementing meaningful health care reform. He discusses the impact of value-based care on the realignment of incentives for patients, providers, and payers.
Future of Health Care: Advancing Innovation and Affordable Healthcare
Unprecedented advances in biomedical innovation such as precision medicine, cell and gene therapies, regenerative medicine, and artificial intelligence require new regulatory and health care delivery paradigms to sustain affordable access for patients and consumers. Dr. Shah discusses the latest trends and opportunities along the arc of innovation that spans from discovery and investment to delivery and payment. How do we bridge the valley that often stands between new medical products and their delivery to the patient’s bedside? What are new potential frameworks for health care that can ensure continued innovation, improve the quality of care, and decrease costs?
